Reading cannabis company financial statements is a fundamental skill that every cannabis investor needs to develop. Cannabis financials are different from those of companies in other industries due to Section 280E taxation, biological asset accounting (Canadian LPs), and the unique revenue mix of a vertically integrated plant-touching business. Understanding these differences is essential for making informed investment decisions.
The income statement is where most investors begin, and it is where cannabis-specific distortions are most apparent. A cannabis income statement follows the standard format — revenue, cost of goods sold, gross profit, operating expenses, operating income, tax, and net income — but the numbers require different interpretation than in other industries.
Revenue in cannabis is composed of wholesale and retail sales, with some companies also reporting licensing, management fees, or ancillary income. Evaluate the mix: retail revenue generally carries higher margins than wholesale. Watch for revenue recognition policies — some companies recognize revenue at the point of sale while others may recognize it at delivery. Consistency matters more than the specific policy, but changes in revenue recognition can artificially inflate or deflate growth rates.
Cost of goods sold (COGS) in cannabis includes cultivation costs, processing, packaging, and in some cases retail labor and occupancy costs. Under Section 280E, cannabis companies have an incentive to allocate as many costs as possible to COGS rather than operating expenses, because COGS is deductible under 280E while operating expenses are not. This means cannabis COGS figures are often inflated compared to similar product companies, and gross margins may appear lower than they would under normal tax treatment.
Gross profit and gross margin are the most comparable metrics across cannabis companies because they sit above the 280E distortion line. Compare gross margins across MSOs, LPs, and the broader sector using Cannabismarketcap's ranking tools. Healthy cannabis gross margins range from 45-55% for well-run MSOs and 30-50% for Canadian LPs. Gross margins below 30% indicate pricing pressure, operational inefficiency, or both.
Operating expenses below the gross profit line are where 280E creates the biggest distortion. In normal industries, selling, general, and administrative (SG&A) expenses are fully deductible from taxable income. For cannabis companies, these expenses are not deductible under 280E. This means a cannabis company's reported operating expenses and income tax are fundamentally different from what they would be in any other industry. You cannot compare a cannabis company's operating margin or net margin to a non-cannabis company's.
The income tax line on cannabis financial statements is often shockingly large relative to pre-tax income. Effective tax rates of 60-80% are common because 280E prevents the deduction of ordinary business expenses. Some cannabis companies show an apparent profit before tax but a net loss after tax — this is the direct result of 280E. When evaluating cannabis profitability, focus on adjusted EBITDA (which adds back taxes, depreciation, and amortization) rather than net income.
The balance sheet tells you about the company's financial health and sustainability. Key items to examine include cash and cash equivalents (the company's war chest), total debt (including current and long-term portions), total equity (and whether it is positive or being eroded by cumulative losses), goodwill and intangible assets (which may be written down in impairments), and biological assets (for Canadian LPs using IFRS accounting).
For Canadian Licensed Producers, biological assets deserve special attention. Under IFRS, cannabis plants in various stages of growth are classified as biological assets and marked to fair value each reporting period. This creates non-cash gains or losses that flow through the income statement and can dramatically distort reported earnings. A Canadian LP might report a large net income driven entirely by a non-cash increase in biological asset fair value, while the actual cash economics of the business are negative. Always strip out biological asset adjustments when analyzing LP profitability.
The cash flow statement is arguably the most important financial statement for cannabis investors because it shows actual cash movement rather than accounting constructs. Operating cash flow reveals whether the core business generates cash. Investing cash flow shows capital expenditure (build-outs, acquisitions). Financing cash flow shows capital raises and debt activity. A company with negative operating cash flow is burning cash and will eventually need to raise more through equity (dilution) or debt.
Free cash flow (operating cash flow minus capital expenditure) is the ultimate measure of a cannabis company's financial self-sufficiency. Positive free cash flow means the company generates enough cash from operations to fund its growth without external financing. Very few cannabis companies achieve this milestone, so improving free cash flow trajectory (becoming less negative each quarter) is a positive sign.
The step-by-step approach to reading cannabis financials starts with the income statement: check revenue growth, gross margin, and whether the 280E-adjusted tax rate is stable or changing. Move to the balance sheet: compare cash to debt, check equity trend, and note any large goodwill balances. Then examine the cash flow statement: is operating cash flow improving? How much capital is being spent? Are they raising cash through dilution or debt? Finally, compare key metrics to sector peers using Cannabismarketcap's screening tools.
Common mistakes when reading cannabis financials include comparing cannabis net margins to other industries (not meaningful due to 280E), taking Canadian LP biological asset gains at face value, ignoring the cash flow statement in favor of income statement metrics, not tracking dilution through the equity section of the balance sheet, and failing to read the notes and MD&A section where management provides context for the numbers.
Use this financial analysis approach every time you evaluate a cannabis stock. The process becomes faster with practice, and the patterns become recognizable. Companies with growing revenue, improving gross margins, positive or improving cash flow, manageable debt, and low dilution deserve premium valuations. Companies with the opposite characteristics deserve caution regardless of how compelling their story sounds.